Email Alert RSS
Volume 13 Issue 6
Nov.  2022
Turn off MathJax
Article Contents
Article Navigation >  Medical Journal of Peking Union Medical College Hospital  > 2022  >  13(6): 1088-1093
LUO Hanhuan, SHI Jie, BIANBA Zhaxi, YANG Xu, NIMA Zhuoma, WANG Qian, LI Mei, WANG Han, LIAO Ruiqian, CIREN Quzhen. Expression of H3K27me3 in Tibetan Patients with Gastric Cancer and Its Significance[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 1088-1093. doi: 10.12290/xhyxzz.2021-0727
Citation: LUO Hanhuan, SHI Jie, BIANBA Zhaxi, YANG Xu, NIMA Zhuoma, WANG Qian, LI Mei, WANG Han, LIAO Ruiqian, CIREN Quzhen. Expression of H3K27me3 in Tibetan Patients with Gastric Cancer and Its Significance[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 1088-1093. doi: 10.12290/xhyxzz.2021-0727
shu

Expression of H3K27me3 in Tibetan Patients with Gastric Cancer and Its Significance

doi: 10.12290/xhyxzz.2021-0727
  • 1.

    Department of Pathology, Tibet Autonomous Region People's Hospital, Lhasa 850000, China

  • 2.

    Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 3.

    Department of General Surgery, Tibet Autonomous Region People's Hospital, Lhasa 850000, China

  • 4.

    Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds:

Tibet Natural Science Funding Committee Grant XZ2017ZR-ZY33

More Information
  • Corresponding author: SHI Jie, E-mail: shijie@pumch.cn
  • Received Date: 2021-11-02
  • Accepted Date: 2021-12-13
  • Publish Date: 2022-11-30
    Abstract
  •   Objective  To investigate the expression and its significance of H3K27me3 in Tibetan patients with gastric cancer.  Methods  Clinical and pathological data were retrospectively collected from Tibetan patients with gastric cancer in the Tibet Autonomous Region People's Hospital from August 2019 to August 2021 and Tibetan non-gastric cancer patients during the same period. The expression of H3K27me3 in gastric cancer tissues, corresponding adjacent normal gastric mucosa and normal gastric mucosa of Tibetan patients with non-gastric cancer tissues was detected by immunohistochemical method, and the differences of H3K27me3 expression between gastric cancer patients with different clinical and pathological characteristics was compared.  Results  A total of 54 Tibetan gastric cancer patients and 55 Tibetan non-gastric cancer patients who met the inclusion and exclusion criteria were enrolled. H3K27me3 was localized in the nucleus, and the nucleus showed brownish-yellow granular staining when positively expressed. The high expression rate of H3K27me3 in gastric cancer tissues was significantly higher than that in adjacent normal gastric mucosa tissue[64.8%(35/54) vs. 29.6%(16/54), P < 0.001]and normal gastric mucosal tissue of Tibetan patients with non-gastric cancer[64.8%(35/54) vs. 34.5%(19/55), P=0.002], and the high expression rate of H3K27me3 in the adjacent normal gastric mucosa tissue was not significantly different from that in normal gastric mucosal tissue of Tibetan patients with non-gastric cancer(P=0.683). H3K27me3 expression in gastric cancer tissues was not related to gender, age, degree of differentiation, depth of invasion, maximum tumor size, Lauren's classification, lymph node metastasis, vascular and nerve invasion and TNM stage.  Conclusions  H3K27me3 is highly expressed in gastric cancer tissues of Tibetan people in Tibet. There is no significant difference in H3K27me3 positive expression cells in adjacent tissues and normal gastric mucosa. The significance of H3K27me3 in Tibetan patients with gastric cancer is uncertain and requires further investigations.
    • FullText(HTML)
  • loading
    • References(20)
  • [1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71: 209-249. doi:  10.3322/caac.21660
    [2] 旦增, 李康, 王中华, 等. 拉萨地区社区人群的胃癌流行病学特征[J]. 世界华人消化杂志, 2013, 21: 2104-2108. https://www.cnki.com.cn/Article/CJFDTOTAL-XXHB201321029.htm

    Dan Z, Li K, Wang ZH, et al. Epidemiological features of gastric cancer in a community population in Lhasa[J]. Shijie Huaren Xiaohua Zazhi, 2013, 21: 2104-2108. https://www.cnki.com.cn/Article/CJFDTOTAL-XXHB201321029.htm
    [3] Kurdistani SK. Histone modifications in cancer biology and prognosis[J]. Prog Drug Res, 2011, 67: 91-106.
    [4] Bates SE. Epigenetic Therapies for Cancer[J]. N Engl J Med, 2020, 383: 650-663. doi:  10.1056/NEJMra1805035
    [5] Xiao W, Zhou Q, Wen X, et al. Small Molecule Inhibitors Overcome Epigenetic Reprogramming for Cancer Therapy[J]. Front Pharmacol, 202, 12: 702360.
    [6] Nam NH, Huong TL, Dung do TM, et al. Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents[J]. Eur J Med Chem, 2013, 70: 477-486. doi:  10.1016/j.ejmech.2013.10.045
    [7] Luu T, Frankel P, Beumer J H, et al. Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial[J]. Cancer Chemother Pharmacol, 2019, 84: 1201-1208. doi:  10.1007/s00280-019-03955-7
    [8] Imai Y, Hirano M, Kobayashi M, et al. HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action[J]. Cancers (Basel), 2019, 11: 475. doi:  10.3390/cancers11040475
    [9] Zang H, Qian G, Zong D, et al. Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat(LBH589)[J]. Cancer, 2020, 126: 2024-2033. doi:  10.1002/cncr.32744
    [10] Tanimoto A, Takeuchi S, Arai S, et al. Histone deacety-lase 3 inhibition overcomes BIM deletion polymorphism-mediated osimertinib resistance in EGFR-Mutant lung cancer[J]. Clin Cancer Res, 2017, 23: 3139-3149. doi:  10.1158/1078-0432.CCR-16-2271
    [11] Zhang L, Zhong K, Dai Y, et al. Genome-wide analysis of histone H3 lysine 27 trimethylation by ChIP-chip in gastric cancer patients[J]. J Gastroenterol, 2009, 44: 305-312. doi:  10.1007/s00535-009-0027-9
    [12] Huang H, Xie L, Feng X, et al. An integrated analysis of DNA promoter methylation, microRNA regulation, and gene expression in gastric adenocarcinoma[J]. Ann Transl Med, 2021, 9: 1414. doi:  10.21037/atm-21-3211
    [13] Li Y, Guo D, Sun R, et al. Methylation Patterns of Lys9 and Lys27 on Histone H3 Correlate with Patient Outcome in Gastric Cancer[J]. Dig Dis Sci, 2019, 64: 439-446. doi:  10.1007/s10620-018-5341-8
    [14] WHO Classification Tumours Editorial Board. WHO classification of tumours of digestive system[M]. Lyon: LARC Press, 2019.
    [15] Samal S, Patnaik A, Sahu F, et al. Altered expression of epigenetic modifiers EZH2, H3K27me3, and DNA methyltransferases in meningiomas-prognostic biomarkers for routine practice[J]. Folia Neuropathol, 2020, 58: 133-142. doi:  10.5114/fn.2020.96970
    [16] 高福利, 吕瑛, 曹俊, 等. H3K27me3在胃癌中的表达及其临床意义[J]. 世界华人消化杂志, 2011, 19: 3597-3602. https://www.cnki.com.cn/Article/CJFDTOTAL-XXHB201135013.htm

    GaoFL, LYU Y, Cao J, et al. Significance of H3K27me3 expression in gastric cancer[J]. Shijie Huaren Xiaohua Zazhi, 2011, 19: 3597-3602. https://www.cnki.com.cn/Article/CJFDTOTAL-XXHB201135013.htm
    [17] He LJ, Cai MY, Xu GL, et al. Prognostic significance of overexpression of EZH2 and H3K27me3 proteins in gastric cancer[J]. Asian Pac J Cancer Prev, 2012, 13: 3173-3178. doi:  10.7314/APJCP.2012.13.7.3173
    [18] 高恩惠, 刘丹, 陈洁, 等. H3K27me3在肿瘤中的表达及其应用[J]. 中国新药与临床杂志, 2021, 40: 406-410. https://www.cnki.com.cn/Article/CJFDTOTAL-XYYL202106002.htm

    Gao EH, Liu D, Chen J, et al. Expression of H3K27me3 in tumors and its application[J]. Zhongguo Xinyao Yu Linchuang Zazhi, 2021, 40: 406-410. https://www.cnki.com.cn/Article/CJFDTOTAL-XYYL202106002.htm
    [19] Hong F, Zhao M, Zhang L, et al. Inhibition of Ezh2 in vitro and the decline of Ezh2 in developing midbrain promote dopami-nergicneurons differentiation through modifying H3K27me3[J]. Stem Cells Dev, 2019, 28: 649-658. doi:  10.1089/scd.2018.0258
    [20] 张宁, 曾智, 阎丽萍, 等. 幽门螺杆菌感染与胃癌中PRC2和H3K27me3的表达关系[J]. 临床研究与应用杂志, 2018, 45: 667-672. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL201813006.htm

    Zhang N, Zeng Z, Yan LP, et al. Relationship between Helicobacter pylori infection and the expression of PRC2 and H3K27me3 in gastric cancer[J]. Linchuang Yanjiu Yu Yingyong Zazhi, 2018, 45: 667-672. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL201813006.htm
    • Relative Articles(0)
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (292) PDF downloads(16) Cited by()
    Proportional views
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return